The U.S. FDA relied on a critically flawed risk-benefit assessment to authorize emergency use of Pfizer’s COVID-19 vaccine for children 5-11 years of age.
The U.S. FDA relied on a critically flawed risk-benefit assessment to authorize emergency use of Pfizer’s COVID-19 vaccine for children 5-11 years of age.